Duvelisib Clinical Trials

6 actively recruiting trials across 5 locations

▲ +1 trial since August 2026

Also known as: 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one, Copiktra, INK-1197, IPI 145, IPI-145 +1 more

Pipeline

Phase 1: 2Phase 2: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

Memorial Sloan Kettering Cancer Center2
SecuraBio1
Jonsson Comprehensive Cancer Center1
City of Hope Medical Center1
Alliance for Clinical Trials in Oncology1

Indications

Cancer6
T-cell Prolymphocytic Leukemia2
Peripheral T-Cell Lymphoma, Not Otherwise Specified2
Follicular Helper T-Cell Lymphoma1
NK-Cell Lymphomas1

Other1 trial

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Phase 3

Little Rock, Arkansas1 trial

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

University of Arkansas for Medical Sciences

Phase 2

Duarte, California1 trial

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

City of Hope Medical Center

Phase 2

Los Angeles, California1 trial

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

David Geffen School of Medicine at the University of California at Los Angeles

Phase 1/2

Miami, Florida1 trial

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

University of Miami (Data Collection Only)

Phase 1

Basking Ridge, New Jersey1 trial

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Memorial Sloan Kettering Basking Ridge (LimitedProtocol Activities)

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.